Growing attention has been given to the role of the
Rho kinase pathway in the development of
heart disease and
ischemia/reperfusion (I/R) injury.
Y-27632 is a
Rho kinase inhibitor demonstrated to protect against I/R injury, but the exact mechanism by which it does so remains to be elucidated. The goal of this project was to determine new targets by which
Y-27632 can protect the heart against I/R injury. Isolated rat hearts were perfused under aerobic conditions or subjected to I/R in the presence or absence of
Y-27632. Administration of
Y-27632 (1 μM) before
ischemia and during the first 10 min of reperfusion resulted in complete recovery of cardiac function. 2-D electrophoresis followed by MS identified four
proteins whose levels were affected by
Y-27632 treatment.
Lactate dehydrogenase and
glyceraldehyde-3-phosphate dehydrogenase were significantly increased in the
Y-27632 treated group, while
creatine kinase was normalized to control levels. In addition, we found increased level of two different molecular fragments of
ATP synthase, which were normalized by
Y-27632. This increase suggests that during
ischemia ATP synthase is subjected to degradation. The changes in metabolic
enzymes' levels and their regulation by
Y-27632 suggest that the cardioprotective effect of
Y-27632 involves increased energy production.